These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30487493)

  • 1. Comparative Study of Alginate and Omeprazole in Symptomatic Treatment of Non-erosive Gastroesophageal Reflux Disease.
    Saifullah AM; Ahmed F; Shil BC; Banik RK; Saha SK; Chowdhury M; Haque A; Alam MS; Akhter A
    Mymensingh Med J; 2018 Oct; 27(4):771-775. PubMed ID: 30487493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
    Chiu CT; Hsu CM; Wang CC; Chang JJ; Sung CM; Lin CJ; Chen LW; Su MY; Chen TH
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1054-64. PubMed ID: 24024757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
    Manabe N; Haruma K; Ito M; Takahashi N; Takasugi H; Wada Y; Nakata H; Katoh T; Miyamoto M; Tanaka S
    Dis Esophagus; 2012 Jul; 25(5):373-80. PubMed ID: 22050449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
    Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
    BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
    Körner T; Schütze K; van Leendert RJ; Fumagalli I; Costa Neves B; Bohuschke M; Gatz G
    Digestion; 2003; 67(1-2):6-13. PubMed ID: 12743434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis.
    Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27671545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole.
    Dettmar PW; Hampson FC; Jain A; Choubey S; Little SL; Baxter T
    Indian J Med Res; 2006 Apr; 123(4):517-24. PubMed ID: 16783042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan.
    Nagahara A; Hojo M; Asaoka D; Sasaki H; Watanabe S
    Scand J Gastroenterol; 2014 Apr; 49(4):409-17. PubMed ID: 24444414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment.
    Xue Y; Zhou LY; Lin SR
    Chin Med J (Engl); 2008 Jul; 121(14):1297-301. PubMed ID: 18713551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].
    Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA
    Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study.
    Miwa H; Inoue K; Ashida K; Kogawa T; Nagahara A; Yoshida S; Tano N; Yamazaki Y; Wada T; Asaoka D; Fujita T; Tanaka J; Shimatani T; Manabe N; Oshima T; Haruma K; Azuma T; Yokoyama T;
    Aliment Pharmacol Ther; 2011 Feb; 33(3):323-32. PubMed ID: 21118395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.